Filing · LD-2 quarterly report
Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$520,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
2
Lobbying activity
2
Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels.
IRC Section 174 amortization of R&D expenditures.